APLS Apellis Pharmaceuticals

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:45 a.m. PT.

The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for approximately 90 days following the event.

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit  or follow us on  and .

Investor Contact: 

Meredith Kaya 

617.599.8178



EN
06/01/2025

Underlying

APLSApellis Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apellis Pharmaceuticals

 PRESS RELEASE
Free
APLS Apellis Pharmac...

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd ...

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net product revenues, including $23 million in 4Q 2024 Expects submission of EMPAVELI sNDA for C3G and primary IC-MPGN in early 2025; U.S. launch anticipated in 2H 2025, if approvedPlans initiation of Phase 3 studies of pegcetacoplan in two additional nephrology indications in 2H 2025Adam T...

January 13, 2025 1 EN
 PRESS RELEASE
Free
APLS Apellis Pharmac...

Apellis Announces Keli Walbert to Join the Board of Directors

Apellis Announces Keli Walbert to Join the Board of Directors WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board. “We are delighted to welcome Keli to the Apellis Board of Directors,” said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. “Keli has a proven track record of successfully bringing novel medicines to...

January 10, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 48.56
VECO Veeco Instrumen...
TER TERADYNE INC. ... (+38)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

VECO VEECO INSTRUMENTS INC.
TER TERADYNE INC.
RRC RANGE RESOURCES CORPORATION
PLUG PLUG POWER INC.
PBYI PUMA BIOTECHNOLOGY INC.
MTDR MATADOR RESOURCES COMPANY
FORM FORMFACTOR INC.
FIVE FIVE BELOW INC.
DAN DANA INCORPORATED
ASPN ASPEN AEROGELS
ASC ARDMORE SHIPPING
OSTK OVERSTOCK.COM INC.
MUR MURPHY OIL CORPORATION
IRBT IROBOT CORPORATION
PAL PANTALEON ENTERTAINMENT ORD SHS
FREY FREY SA
FI FRANK'S INTERNATIONAL NV
OXM OXFORD INDUSTRIES INC.
TTI TETRA TECHNOLOGIES INC.
AEHR AEHR TEST SYSTEMS
SD SANDRIDGE ENERGY INC.
DK DELEK US HOLDINGS INC
APLS APELLIS PHARMACEUTICALS
LBRT LIBERTY OILFIELD SERVICE
TDW TIDEWATER INC
INSP INSPIRE MEDICAL SYSTEMS
BORR BORR DRILLING
LPI LAREDO PETROLEUM INC.
FET FORUM ENERGY TECHNOLOGIES
POWW AMMO INC
SHLS SHOALS TECHNOLOGIES GROUP
VAL VALARIS LTD
SEAT HORIZON ACQUISITION CORP
SKIN THE BEAUTY HEALTH CO
QDEL QUIDEL CORP
NE NOBLE CORP (NEW)
NXT NEXTRACKER INC.
VCSA VACASA INC.
01/09/25 January 9, 2025 1 EN
 PRESS RELEASE
Free
APLS Apellis Pharmac...

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listi...

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of January 2, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were app...

January 7, 2025 1 EN
 PRESS RELEASE
Free
APLS Apellis Pharmac...

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Heal...

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:45 a.m. PT. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, ...

January 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch